Is DexCom (DXCM) A Bargain On FDA Cleared Stelo Expansion?

Simply Wall St.07:12

AdvertisementFDA clearance for Stelo expansion puts DexCom (DXCM) back in focus DexCom (DXCM) is back on investors’ radar after the FDA cleared expanded use of its Stelo Glucose Biosensor for children...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2647349773?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2026-06-29 07:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647349773","market":"nz","top_or_hot":-1,"title":"Is DexCom (DXCM) A Bargain On FDA Cleared Stelo Expansion?","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementFDA clearance for Stelo expansion puts DexCom (DXCM) back in focus DexCom (DXCM) is back on investors’ radar after the FDA cleared expanded use of its Stelo Glucose Biosensor for children...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-dxcm/dexcom/news/is-dexcom-dxcm-a-bargain-on-fda-cleared-stelo-expansion\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is DexCom (DXCM) A Bargain On FDA Cleared Stelo Expansion?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs DexCom (DXCM) A Bargain On FDA Cleared Stelo Expansion?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-29 07:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-dxcm/dexcom/news/is-dexcom-dxcm-a-bargain-on-fda-cleared-stelo-expansion><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementFDA clearance for Stelo expansion puts DexCom (DXCM) back in focus DexCom (DXCM) is back on investors’ radar after the FDA cleared expanded use of its Stelo Glucose Biosensor for children...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-dxcm/dexcom/news/is-dexcom-dxcm-a-bargain-on-fda-cleared-stelo-expansion\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0354030511.USD","symbol_name":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-dxcm/dexcom/news/is-dexcom-dxcm-a-bargain-on-fda-cleared-stelo-expansion","article_id":"2647349773","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-dxcm/dexcom/news/is-dexcom-dxcm-a-bargain-on-fda-cleared-stelo-expansion","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2647349773","pubTimestamp":1782688338,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"FDA clearance for Stelo expansion puts DexCom (DXCM) back in focus\nDexCom (DXCM) is back on investors’ radar after the FDA cleared expanded use of its Stelo Glucose Biosensor for children aged 2 and older who do not use insulin, along with new international rollout plans.\nSee our latest analysis for DexCom.\nAfter the FDA clearance, DexCom’s recent 1 day share price return of 2.17% contrasts with a softer 7 day share price return of 3.22% and a 30 day share price return of 4.88%. The 90 day...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","DXCM":"德康医疗","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LABU":"三倍做多标普生物-Direxion","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","BK4082":"医疗保健设备","BK4504":"桥水持仓","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","BK4588":"碎股","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","BK4548":"巴美列捷福持仓","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","BK4551":"寇图资本持仓","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC"},"translate_title":"DexCom(DXCM)在FDA批准的Stelo扩张上是否划算？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"DXCM":1.5},"content_text":"AdvertisementFDA clearance for Stelo expansion puts DexCom (DXCM) back in focus DexCom (DXCM) is back on investors’ radar after the FDA cleared expanded use of its Stelo Glucose Biosensor for children aged 2 and older who do not use insulin, along with new international rollout plans. See our latest analysis for DexCom. After the FDA clearance, DexCom’s recent 1 day share price return of 2.17% contrasts with a softer 7 day share price return of 3.22% and a 30 day share price return of 4.88%. The 90 day share price return of 13.31% sits against a 1 year total shareholder return that declined 18.75% and a 3 year total shareholder return that declined 45.42%, suggesting short term momentum has picked up even as longer term holders remain under pressure. If this kind of regulatory driven move has your attention, it could be a useful moment to broaden your research and check out 39 healthcare AI stocks With DexCom trading at an intrinsic discount estimate of about 40%, and roughly 22% below the average analyst price target, are investors looking at a genuine value opportunity here, or is the market already pricing in future growth? Most Popular Narrative: 15.9% Undervalued Compared with DexCom’s last close at $70.14, the most followed valuation narrative points to a higher fair value, framing today’s price as a discount worth examining.  The recent expansion of insurance reimbursement for type 2 non-insulin diabetes patients, now covering nearly 6 million lives across the three largest U.S. PBMs, opens a large, previously untapped segment of DexCom's addressable market, driving new patient growth and supporting robust multi-year revenue expansion.  Read the complete narrative. Want to see what sits behind that view? The narrative leans on steady revenue gains, firmer margins and a valuation multiple that assumes investors stay comfortable with long term earnings power. Result: Fair Value of $83.42 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, DexCom’s story still carries risks, particularly potential pricing pressure from proposed CMS competitive bidding and the threat of stronger competition in core CGM markets. Find out about the key risks to this DexCom narrative. Another view on DexCom's valuation While the narrative-led fair value suggests DexCom is undervalued, the current P/E of 29.1x tells a tighter story. It sits above the US Medical Equipment industry at 26.2x and also above peer average at 21.3x, yet is close to a fair ratio estimate of 29.5x. That narrow gap implies the share price may already reflect much of the current earnings profile, so the focus may now be more on future delivery rather than on today's discount. For a closer look at how the current P/E compares with what the market could move toward, check the See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:DXCM P/E Ratio as at Jun 2026Next Steps If this mix of short term momentum, valuation debate and FDA news around DexCom leaves you curious, take a moment to test the numbers yourself and stress test the narrative before markets move on. To see which potential bright spots our model is flagging, review the 4 key rewards Looking for more investment ideas beyond DexCom? Do not stop your research with DexCom. Widen your watchlist now or you risk missing stocks that better match your goals, risk profile and time horizon.  Target potential mispricing by scanning for companies trading below assessed worth using the 44 high quality undervalued stocks. Prioritize resilience by focusing on businesses with strong finances through the solid balance sheet and fundamentals stocks screener (48 results). Strengthen potential income streams by reviewing companies offering higher yields via the 8 dividend fortresses.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2647349773","isCrawlerRequest":true}